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Abstract
Results from whole-genome association studies of many common diseases are now available.
Increasingly, these are being incorporated into meta-analyses to increase the power to detect weak
associations with measured single-nucleotide polymorphisms (SNPs). Imputation of genotypes at
unmeasured loci has been widely applied using patterns of linkage disequilibrium (LD) observed in
the HapMap panels, but there is a need for alternative methods that can utilize the pooled effect
estimates from meta-analyses and explore possible associations with SNPs and haplotypes that are
not included in HapMap.
By a weighted average technique, we show that a s s o c i a t i o nr e s u l t sf o rc o m m o nS N P si na n
observed data set can be scaled and combined to infer the effect of a genetic variant that has been
measured only in an independent reference data set. We show that the ratio p(R-1)/[1 + p(R-1)],
where R is the relative risk associated with a measured or unmeasured allele of frequency p,i s
appropriately scaled by 1/D’ a n dw e i g h t e di np r o p o r t i o nt or
2, both common measures of LD being
derived from the reference data set.
We illustratethiscomputationally simple methodbycombiningthe resultsof a genome-wideassociation
screen from the North American Rheumatoid Arthritis Consortium with LD measures from the British
1958 Birth Cohort, and explore the validity of underlying assumptions about the generalizability of LD
from one population to another, and from healthy subjects to subjects with clinical disease.
Background
The HLA allele DRB1*04 has been shown to be more
strongly associated with rheumatoid arthritis than
nearby tagging single-nucleotide polymorphisms
(SNPs) [1]. We propose here a method of inferring the
effects of an unmeasured genetic variant (such as
DRB1*04) using linkage disequilibrium (LD) measures
from an independent reference data set (the British 1958
P a g e1o f6
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Open AccessBirth Cohort) to scale and weight the associations of
rheumatoid arthritis with tagSNPs in the North Amer-
ican Rheumatoid Arthritis Consortium (NARAC) data
set, supplied as Problem 1 for the Genetic Analysis
Workshop 16.
Methods
The British 1958 Birth Cohort (B58C) compromises all
infants in England, Wales, and Scotland born in one
week in 1958. During a follow-up in 2002 to 2004 [2], a
cell-line-backed DNA collection was established as a
nationally representative reference set for genetic case-
control studies. Field protocols and consent forms were
approved by the South East England Multi-Centre
Research Ethics Committee. Genome-wide data from
the Illumina HumanHap550 Beadarray on 1430 mem-
bers of the B58C was deposited by the Wellcome Trust
Sanger Institute [3]. In addition, data on HLA typing
using Dynal technologies were deposited by the Diabetes
& Inflammation Laboratory, Cambridge [4]. Further
details about these deposits and the B58C DNA
Collection are published online [5].
The NARAC data set [6], provided as Problem 1 for the
Genetic Analysis Workshop 16, consists of individual-
level genotype data for 550,000 SNPs tested on the
I l l u m i n aH u m a n H a p 5 5 0B e a dA r r a yl i n k e dt oc a s e /
control status for rheumatoid arthritis as well as the HLA
alleles at the DRB1 locus. We derived a numerical score
to represent the number of DRB1*04 alleles for each
individual in both the NARAC and B58C data sets.
Association tests between the rheumatoid arthritis case/
control status and each tagSNP in the MHC region
(chromosome 6; 27-33 Mb [7]) were generated using
Stata™ 9.2.
We tested whether combining the LD patterns from the
B58C and the association patterns from NARAC provide
an unbiased estimate the effect of the DRB1*04 allele,
using only neighboring tagSNPs (± 300 kb) that are
common to both data sets. This application has the
advantage that the DRB1*04 allele (our target variant)
has been measured directly in both data sets, permitting
validity checks between our inferred relative risk estimate
and the observed effect in the NARAC case-control study.
We define Fobs = q(Robs-1)/[1 + q(Robs-1)], where Robs is
the relative risk of disease associated with each copy of a
measured allele of frequency q. The expression for F is
similar to that for the population-attributable risk
fraction (PARF) in epidemiological studies. However,
in this genetic application, because each individual has
two chromosomes, the PARF of a variant is F(2-F). In
the Appendix we show that when the tagSNP is more
common than the target variant, Fobs/D’ is an unbiased
estimator of Ftrue,w h e r eFtrue is the equivalent
parameter at the unmeasured target locus and D’ is the
conventional measure of LD between the measured
tagSNP and the target variant in an undiseased popula-
tion. We also show (see Appendix) that, for any given
target variant and study design, the variance of Fobs for
each tagSNP under the null hypothesis is inversely
proportional to the LD measure r
2, relating the measured
tagSNP to the unmeasured target variant in the undi-
seased population.
We calculated a weighted average of the values of Finfer =
Fobs/D’ across all tagSNPs in the selected 600-kb region,
and derived an inferred relative risk from this pooled
estimate of F. In this paper we explore the effect of
different assumptions about the generalizability of LD
measures and selection of tagSNPs upon this point
estimate. An empirical variance of this pooled estimate
under the null hypothesis was derived from multiple
random permutations of the B58C data set.
Results
Individually linked HLA-DRB1 diplotypes and Illumina
HumanHap550 genotypes were available for 1217
members of B58C and for 1187 controls and 799 cases
from NARAC. The frequency of DRB1*04 was 21.1% in
the B58C reference set, 16.5% in the NARAC controls
and 52.2% in the NARAC cases. Counting chromosomes
among cases and controls, the observed odds ratio of
rheumatoid arthritis per copy of the DRB1*04 variant
was 5.54 (95%CI 4.78-6.41) corresponding to a F of
0.4280.
All subsequent data relates to 156 SNPs common to both
data sets where the minor allele frequency (MAF) of the
tag is greater than that of DRB1*04, also less than 44% in
the reference data set and |D| > 0.01, where D is the
covariance measure of LD. These restrictions are imposed
to remove SNPs where the effect allele could be
inconsistent between the B58C data and the NARAC
controls data.
For general application, the method needs to apply
measures of LD derived from a reference data set to the
observed data set where the target variant has not been
measured. Figure 1 shows good correspondence for all
measures of LD between B58C and NARAC controls. Our
inference method assumes that the s measure of LD (see
Appendix for definition) is constant between cases and
controls. In this example, even where there is a strong
association between the target variant and disease, this
assumption appears valid, as shown in Figure 2. In most
situations, the association of the target variant with
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unknown and estimated from the reference data set (e.g.,
B58C). Using D’ and r
2 from the B58C data, the pooled
estimate of F is 0.4530, which is very close to the value of
0.4280 derived directly in the NARAC case-control data.
The variance of the pooled estimate of F is greater than
the sum of the weights, because many of the neighboring
tagSNPs are intercorrelated. The precision of this pooled
estimate was estimated by performing 1000 random
permutations of the B58C data set to derive the variance
of the pooled estimate under the null hypothesis. These
results are summarized in Table 1. Inclusion of all 156
SNPs generated a pooled estimate of similar magnitude
and precision to that from the three most closely
associated SNPs. On the other hand, if no closely
associated tagSNPs had been available, results with
similar magnitude and only slight loss of precision
could be obtained from the majority of SNPs with
r
2 < 0.3. Indeed, in this example, from a region of high
LD (D’ > 0.5), useful information could be derived even
from tagSNPs with r
2 <0 . 1 .
Conclusion
Comparing B58C to the NARAC controls, there was close
correspondence in LD patterns. Within the NARAC data,
however, the LD measures r
2 and t in the region of
interest were markedly different in cases and controls,
reflecting the strong association between the target
variant (DRB1*04) and rheumatoid arthritis. When
compared with imputation approaches, the inference
method has the advantage of working only with the LD
pattern among controls, although it does assume
generalizability of the sensitivity parameter s from
controls to cases. This latter assumption was supported
in the NARAC data. The inference approach that we
describe can, with modification, be applied to contin-
uous outcomes and offers an alternative to imputation
Figure 1
LD measures in NARAC controls versus B58C. Clockwise from top left: a) r
2,b )D', c) s, and d) t. See Appendix for
description of s and t.
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variants that are not part of standard panels such as
HapMap, and for exploring further genome-wide sets of
association measures that have been derived from meta-
analysis of a particular disease or quantitative trait.
List of abbreviations used
B58C: British 1958 Birth Cohort; LD: Linkage disequili-
brium; NARAC: North American Rheumatoid Arthritis
Consortium; PARF: Population-attributable risk fraction;
SNPs: Single-nucleotide polymorphisms.
Figure 2
LD measures in NARAC controls versus case. Clockwise from top left: a) r
2,b )D', c) s,a n dd )t. See Appendix for
description of s and t.




0 0.2 0.4 0.6 0.1 0.3 0.5 0.7
Pooled F 0.453 0.4046 0.4065 0.4253 0.3768 0.5104 0.4569 0.4530
SE of pooled F 0.0258 0.0256 0.0256 0.0256 0.0352 0.0292 0.0263 0.0257
Number of tagSNPs used in estimate 156 21 12 3 102 135 153 156
Different combinations of tagSNPs from the NARAC case-control data set, selected by inclusion based on r
2 between the tagSNPs and the DRB1*04
allele, give slightly different effect estimates (F). Also shown is the standard error of F under the null hypothesis, derived empirically from
1000 random permutations of the B58C data set.
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Within a total population, the LD between each tagSNP
and an unmeasured target variant may be represented by
Table 2, based on relative counts of chromosomes. The
parameter s represents the proportion of the target
variant that also has the tagSNP variant (akin to
sensitivity in screening terminology). Another measure,
equivalent to the positive predictive value, is t (= sp/q),
the proportion of chromosomes with the tagSNP allele
that also have the target variant. We seek to infer a value
for the true relative risk (R) from the measured relative
risk (Robs) associated with each tagSNP.
We define a transformation of R,a sf o l l o w s :
ΦΦ true obs  and  =− +− = − + − pR pR qR qR obs obs () / [() ] ( ) / [( ) ] . 11 1 11 1
We show below that Fobs/D’ is an unbiased estimator of
Ftrue.
In Table 2: Ib = Io [R (1-s)p+(1-q)-(1-s)p]/[1-q],
so : / [ ( )]/[ ]
[ ( )( ) ( )(
I I pR spR p sp q q
pR q pR s q
bo =−− + + − −
=−− − −−
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11 1 ) )( ) ] / [ ]
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We infer values of Finfer = Fobs/D’ for each tagSNP and
derive a weighted average, with weights inversely
proportional to their variance under the null hypothesis.
An approximate variance for Finfer can be derived by the
D e l t am e t h o db yc o n s i d e r i n gFobs as a function of p, q,
D’ and b =l n ( Robs), as follows, noting that:
Φobs f
f u n
== − + −
′ =+ − =
( ) () / [ () ]
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2 d der the null hypothesis ( ). RR obs == 1
Also, if R = Robs =1 ,a n dc is the proportion of N
chromosomes that come from cases:
Var( ) /[ ( )]] [ /[ ( )]] [ / ], β =− ∗− ∗ 11 11 1 qq cc N
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2 1 11 −∗ cN )]] [ / ].
Inverse-variance weights proportional to the LD measure
r
2 are therefore appropriate because p (the minor allele
frequency for the target variant) is the same for all tag
SNPs and c and N are fixed by the study design.
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